Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Reich, Kristian ; Papp, Kim A ; Blauvelt, Andrew ; Langley, Richard G ; Armstrong, April ; Warren, Richard B ; Gordon, Kenneth B ; Merola, Joseph F ; Okubo, Yukari ; Madden, Cynthia ; Wang, Maggie ; Cioffi, Christopher ; Vanvoorden, Veerle ; Lebwohl, Mark

The Lancet (British edition), 2021-02, Vol.397 (10273), p.487-498 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível